Cargando…

200. Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against AmpC Hyperproducing Enterobacterales and P. aeruginosa Collected from United States (US) Medical Centers (2016-2020)

BACKGROUND: E. cloacae species complex (ECL), S. marcescens (SM), C. freundii species complex (CF), and P. aeruginosa (PSA) are common pathogens in a variety of clinical infections. These organisms can overexpress the chromosomal AmpC that encodes resistance to several β-lactams. We evaluated the ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sader, Helio S, Carvalhaes, Cecilia G, Mendes, Rodrigo E, Castanheira, Mariana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Oral Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643914/ http://dx.doi.org/10.1093/ofid/ofab466.200

Ejemplares similares

202. Comparative Activity of Ceftazidime-Avibactam, Imipenem-Relebactam and Meropenem-Vaborbactam Tested Against Carbapenem-Nonsusceptible Enterobacterales that Are Carbapenemase-Negative
por: Castanheira, Mariana, et al.
Publicado: (2021)

2146. Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-avibactam, and Meropenem-vaborbactam against Enterobacterales causing Bloodstream Infection in US Medical Centers (2020–2022)
por: Sader, Helio S, et al.
Publicado: (2023)

1686. Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic Fibrosis Patients
por: Sader, Helio S, et al.
Publicado: (2022)

1284. Occurrence of β-Lactamases among Enterobacterales Isolated from United States Hospitals: Results of the INFORM Surveillance Program for Ceftazidime-Avibactam
por: Castanheira, Mariana, et al.
Publicado: (2021)

1443. Activity of Ceftazidime-Avibactam against Carbapemenase-negative Carbapenem-resistant Enterobacterales (CRE) Isolates from US Hospitals
por: Castanheira, Mariana, et al.
Publicado: (2020)

Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates
por: Castanheira, Mariana, et al.
Publicado: (2021)

Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019–2021)
por: Sader, Helio S, et al.
Publicado: (2023)

26. in Vitro selection Of enterobacter Cloacae with Cefepime, Meropenem, and Ceftazidime-avibactam Generate Diverse Resistance Mechanism
por: Castanheira, Mariana, et al.
Publicado: (2020)

Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States (US) Medical Centers (2013–2016)
por: Sader, Helio S, et al.
Publicado: (2017)

Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021)
por: Sader, Helio S., et al.
Publicado: (2023)

Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents
por: Castanheira, Mariana, et al.
Publicado: (2022)

2756. Activity of Aztreonam-avibactam and Ceftazidime-avibactam against United States Isolates Producing β-lactamases (2020–2021)
por: Castanheira, Mariana, et al.
Publicado: (2023)

129. Antimicrobial Activity of Ceftazidime–avibactam and Comparator Agents Tested against Gram-Negative Organisms Isolated from Patients with Bloodstream Infections in United States Medical Centers (2017–2018)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2019)

1687. Antimicrobial Activity of Ceftibuten-Avibactam against a Global Collection of Enterobacterales from Patients with Complicated Urinary Tract Infections (2021)
por: Sader, Helio S, et al.
Publicado: (2022)

Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients
por: Sader, Helio S, et al.
Publicado: (2021)

Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Enterobacteriaceae and Pseudomonas aeruginosa from United States (US) Medical Centers Stratified by Infection Type (2015–2016)
por: Sader, Helio S, et al.
Publicado: (2017)

2214. Comparison of Cefepime–Zidebactam (WCK 5222), Ceftazidime–Avibactam, and Ceftolozane–Tazobactam Tested Against Gram-Negative Organisms Causing Pneumonia in United States Hospitals in 2018
por: Sader, Helio S, et al.
Publicado: (2019)

1238. Comparative Activity of Meropenem-Vaborbactam and Ceftazidime-Avibactam Against Multidrug-Resistant Enterobacter cloacae from Hospitals in Europe and United States
por: Castanheira, Mariana, et al.
Publicado: (2021)

1949. Activity of Aztreonam-Avibactam against Enterobacterales Resistant to Recently Approved Beta-Lactamase Inhibitor Combinations Collected Worldwide (ex-US; 2020–2022)
por: Sader, Helio S, et al.
Publicado: (2023)

Impact of systematic screening for AmpC-hyperproducing Enterobacterales intestinal carriage in intensive care unit patients
por: Manquat, Elsa, et al.
Publicado: (2020)

Correction to: Impact of systematic screening for AmpC-hyperproducing Enterobacterales intestinal carriage in intensive care unit patients
por: Manquat, Elsa, et al.
Publicado: (2021)

37. Bloodstream Infections in the United States and Europe: Etiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2016–2019)
por: Sader, Helio S, et al.
Publicado: (2020)

1436. Comparison of Ceftazidime–Avibactam, Ceftolozane–Tazobactam, Piperacillin–Tazobactam, and Meropenem Activities When Tested Against Gram-Negative Organisms Isolated From Complicated Urinary Tract Infections
por: Sader, Helio S, et al.
Publicado: (2019)

Characterization of Enterobacter and Citrobacter spp. Isolates from United States Hospitals by Whole-Genome Sequencing Analysis and Activity of Ceftazidime-Avibactam and Comparator Agents
por: Castanheira, Mariana, et al.
Publicado: (2017)

1592. Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Against Enterobacterales and Pseudomonas aeruginosa With Overexpression of AmpC β-Lactamase From Phase 3 Clinical Trials
por: Lin, Lynn-Yao, et al.
Publicado: (2020)

2755. Activity of Aztreonam-avibactam and Carbapenem-resistant Enterobacterales (CRE) Isolates Collected in a Six-year Period (2017–2022)
por: Castanheira, Mariana, et al.
Publicado: (2023)

2427. Comparison of Ceftazidime–Avibactam and Ceftolozane-Tazobactam In Vitro Activities When Tested Against Gram-Negative Bacteria Isolated From Patients Hospitalized With Pneumonia in US Medical Centers (2017)
por: Sader, Helio S, et al.
Publicado: (2018)

Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019–21)
por: Sader, Helio S, et al.
Publicado: (2023)

Characterization of Enterobacter cloacae and Citrobacter freundii species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of ceftazidime/avibactam and comparator agents
por: Sader, Helio S, et al.
Publicado: (2021)

1684. Antimicrobial Activity of Aztreonam-Avibactam Against a Large Collection of Stenotrophomonas maltophilia and Burkholderia cepacia Species Complex Causing Infections in United States (US) Medical Centers (2016-2021)
por: Sader, Helio S, et al.
Publicado: (2022)

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents Tested against Contemporary (2016) Clinical Enterobacteriaceae Isolates
por: Sader, Helio S, et al.
Publicado: (2017)

1523. Antimicrobial Activity of Ceftazidime–Avibactam and Comparator Agents Tested Against Gram-Negative Organisms Isolated from Complicated Urinary Tract Infections: Results from the International Network for Optimal Resistance Monitoring (INFORM) Program
por: Sader, Helio S, et al.
Publicado: (2018)

Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam
por: Atkin, Stan D, et al.
Publicado: (2018)

250 Ceftazidime-avibactam Activity Tested Against a Large Collection of Enterobacteriaceae Isolates Collected in United States (USA) Hospitals in the 2011-2013 Period, Including Organisms Producing KPC- and CTX-M-variants
por: Castanheira, Mariana, et al.
Publicado: (2014)

Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019
por: Mendes, Rodrigo E, et al.
Publicado: (2021)

1229. Antimicrobial Activity of Plazomicin against Multidrug-resistant Enterobacterales: Results from 3 Years of Surveillance in Hospitals in the United States (2018–2020)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2021)

1261. Antimicrobial Activity of Aztreonam-Avibactam against Gram-negative Bacteria Isolated from Patients Hospitalized with Pneumonia in Europe, Latin America, and Asia in 2019
por: Sader, Helio S, et al.
Publicado: (2020)

2801. Antimicrobial Spectrum of Plazomicin and Other Aminoglycosides against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales When Applying New Breakpoints
por: Sader, Helio S, et al.
Publicado: (2023)

1278. Impact of Different Breakpoint Criteria on the Susceptibility Rates of Enterobacterales resistant Subsets to the Aminoglycosides
por: Sader, Helio S, et al.
Publicado: (2020)

Ceftolozane/Tazobactam Activity Against Drug-Resistant Pseudomonas aeruginosa and Enterobacterales Causing Healthcare-Associated Infections in Eight Asian Countries: Report from an Antimicrobial Surveillance Program (2016–2018)
por: Pfaller, Michael, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lkarce1md6k1qq6tvb6nsgtrqt